HPA-1a alloimmunisation: how often the higher-risk mother actually forms antibodies

Design

Prospective, non-interventional natural history study, 28 sites

Population

14,114 pregnant women without prior FNAIT, screened at 10–14 weeks

Primary outcome

New anti-HPA-1a antibodies in higher-risk women by 10 weeks postpartum

Effect

2 of 19 (11%; 95% CI 1.3% to 33.1%); 1.7% were HPA-1b/1b

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is rare but can cause intracranial haemorrhage, usually from maternal antibodies against the HPA-1a platelet antigen. A prospective natural history study screened 14,114 pregnant women at 10–14 weeks across 28 sites in North America and Europe, using a stepwise algorithm: maternal HPA-1 genotype, then HLA-DRB3*01:01 status, then antibody status, then fetal genotype.

About 1.7% of women were HPA-1b/1b, with variation by ancestry and region. Twenty-four met the full higher-risk definition. Of the 19 with postpartum testing, 2 had formed anti-HPA-1a antibodies by 10 weeks after birth. A further 18 women already had antibodies at screening.

The absolute numbers are small and the confidence interval for the alloimmunisation rate is wide. Routine population screening for HPA-1a is not standard practice, and this study does not change that. Its value is in giving a clearer picture of who is at risk and how often, which matters as prophylactic approaches are being developed.

• Take a careful history for a previous baby with unexplained neonatal thrombocytopenia or intracranial bleeding — that is the main trigger for FNAIT work-up today.
• Refer women with a history of FNAIT to fetal medicine early in the next pregnancy; recurrence risk is high.
• Know that about 1.7% of women in this multi-ethnic cohort were HPA-1b/1b, the genotype that can form anti-HPA-1a antibodies.
• Expect pre-existing antibodies in some first-time-tested women, which is why screening at 10–14 weeks found cases before any delivery.

Why it matters

These are among the first prospective, multi-ethnic estimates of how often a higher-risk mother actually becomes alloimmunised.

Don't overread it

With 19 women followed, the 11% alloimmunisation figure is very imprecise and does not justify universal screening on its own.

The statistics, in plain English

Two of 19 is 11%, but the 95% confidence interval runs from 1.3% to 33.1% — a small sample can only narrow the estimate so far. Five of the 24 higher-risk women were lost before postpartum testing, which could move the true figure either way.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.